Abrysvo, the vaccine for Respiratory Syncytial Virus that is promoted without its efficacy and safety being well demonstrated

2023-12-10 13:02:17

It seems to be “in fashion” Respiratory syncytial virus (VRS). And it coincides with the promotional campaign for a new treatment against it, Beyfortus (nirsevimab), which It has been falsely classified as a “vaccine”and now yes, with a new vaccine against that virus: Abrysvo.

This is the first vaccine against RSV with indication for protection of the infantfrom birth to 6 months of age after maternal immunization during pregnancy, and protection of people over 60 years of age.

Well, if the first is a new economic-health hit (a drug without proven efficacy, dangerous and expensive), let’s see what the vaccine will bring us.

To begin with, the Product data sheetthe official document about it, says:

Safety and effectiveness have not been established of Abrysvo in children (from birth to 18 years of age). Available data on pregnant adolescents and their babies are limited«.

Technical data sheet of the drug.

That is, it is about protecting infants with a product whose efficacy and safety are not yet known.

Important Also: The vaccine should not be mixed with any other vaccine or medication.

At Abrysvo the efficacy and safety of the vaccine has NOT been evaluated in immunocompromised peopleincluding those receiving immunosuppressive treatment.

Nor has it been studied in pregnant women less than 24 weeks pregnant. Since infant protection against RSV depends on the transfer of maternal antibodies across the placenta, Abrysvo should be administered between 24 and 36 weeks of pregnancy.

It is unknown whether this vaccine is excreted in breast milk. And the health authorities say that they have not been observed adverse effects with Abrysvo in breastfed newborns of vaccinated mothers.

And “as with any vaccine, it is possible that no immune response occurs protective after vaccination.

Regarding side effects, the sheet comments that they are usually mild or moderate, but not serious. However, he does recognize that in the study with people over 60 years of age there were some cases of Guillain Barre syndrome (a rare disorder in which one’s own immune system a person damages their neurons and causes muscle weakness and sometimes paralysis).

Another interesting thing to know is that the European Medicines Agency has granted the licensee a postponement to present the results of the trials carried out with Abrysvo in children from 2 to less than 18 years of age. Wow, the treatment is being studied.

By the way, among the excipients, there is the controversial polysorbate 80 that he Chile’s Ministry of Health, for example, says in a communication:

They have also been associated with serious adverse events, including death«.

Government of Chile.

Oh, and finally, and as with the other RSV injectable, Beyfortus (I leave you below the post about it that we published recently), there is the issue of conflicts of interest.

The new treatment for childhood bronchiolitis, Beyfortus: ineffective, expensive and dangerous

Coincidences of life, among doctors who are promoting Beyfortus is the pediatrician Federico Martinónwho has received from the pharmaceutical companies 283,573 euros, in two years (Pfizer, GSK, Sanofi o AstraZeneca).

Well, this man is one of the main researchers of the GENVIP (Genetics, Vaccines, Infections and Pediatrics), the development team of the Abrysvo vaccine.

So we have a product of which little is known about its effectiveness and safety and which presents various problems and contraindications. Which is going to be administered to infants… and do you know what is the most effective way to prevent bronchiolitis? Well, something as simple and natural as breastfeeding itself! So This study indicates made in Spain.

Everyone draws their own conclusions.

Related